unknown
Stage
About
Intrommune Therapeutics develops toothpaste-based oral mucosal immunotherapy (OMIT) products that embed food proteins to desensitize patients to food allergies, enabling daily administration during routine tooth brushing. The company is focused on creating a safe, disease-modifying treatment for food allergies.
Explore Intrommune Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.